Publications

Fluoroquinolone-resistant Streptococcus pneumoniae, an emerging but unrecognized public health concern: Is it time to resight the goalposts? by Ambrose PG, Bast D, Doern GV, Iannini PB, Jones RN, Kuglman KP and Low DE published in Clin. Infect. Dis. 2004; 39 (10): 1554-1556; author reply 1556-1557

Surveillance in Taiwan using molecular epidemiology for extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. by Yu W-L, Winokur PL, Jones RN and Sader HS published in Infect. Control Hosp. Epidemiol. 2004; 25 (10): 812-818

Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. by Pfaller MA, Espinel-Ingroff A, Jones RN published in J. Clin. Microbiol. 2004; 42 (10): 4577-4580

Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. by Deshpande L, Rhomberg PR, Fritsche TR, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 50 (1): 73-75

Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). by Bidenbach DJ, Moet GJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 50 (1): 59-69

Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American Hospitals: Report from the SENTRY Antimicrobial Surveillance Program. by Gales AC, Andrade SS, Sader HS and Jones RN published in J. Chemother. 2004; 16 (4):323-328

Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM415), a novel inhibitor of bacterial peptide deformylase. by Fritsche TR, Moet GJ, Jones RN published in Clin. Microbiol. Infect. 2004; 10 (9): 857-860

Resistance Trends of Acinetobacter spp. in Latin America and Characterization of International Dissemination of Multi-Drug Resistant Strains: Five-Year Report of the SENTRY Antimicrobial Surveillance Program. by Tognim MCB, Andrade SS, Silbert S, Gales AC, Jones RN and Sader HS published in Int. J. Infect. Dis. 2004; 8 (5): 284-291

Evaluation of the contemporary occurrence rates of metallo-beta-lactamases in multidrug-resistant Gram-negative bacilli in Japan: Report from the SENTRY Antimicrobial Surveillance Program (1998-2002). by Jones RN, Deshpande LM, Bell JM, Turnidge JD, Kohno S, Hirakata Y, Ono Y, Miyazawa Y, Kawakama S, Inoue M, Hirato Y and Toleman MA published in Diagn. Microbiol. Infect. Dis. 2004; 49 (4): 289-294

Results of two worldwide surveys into physician awareness and perceptions of extended-spectrum beta-lactamases. by Goossens H, Malhotra-Kumar S, Eraksoy H, Unal S, Grabein B, Masterton R, Mendes C, Garcia-Rodriguez J-A, Russo G and Jones RN published in Clin. Microbiol. Infect. 2004; 10 (8):760-762

Molecular epidemiology of selected multidrug-resistant bacteria: A global report from the SENTRY Antimicrobial Surveillance Program. by Deshpande LM, Fritsche TR, Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 49 (4): 231-236

Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: A sample of North American isolates. by Sader HS, Streit JM, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 49 (4): 283-287

Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of year five (2003). by Rhomberg PR, Jones RN, Sader HS, Fritsche TR published in Diagn. Microbiol. Infect. Dis. 2004; 49 (4): 273-281

Activities of doripenem (S-4661) against drug-resistant clinical pathogens. by Jones RN, Huynh HK, Biedenbach DJ published in Antimicrob. Agents. Chemother. 2004; 48 (8): 3136-3140

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. by Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS published in J. Antimicrob. Chemother. 2004; 54 (1): 144-154

Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: Report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). by Streit JM, Jones RN, Sader HS and Fritsche TR published in Int. J. Antimicrob. Agents 2004; 24 (2): 111-118

Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: Spectrum of antimicrobial activity and measurements of bactericidal activity. by Sader HS, Fedler KA, Rennie RP, Stevens S and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (8): 3112-3118

Does the use of antibiotics in food animals pose a risk to human health? A reply to critics. by Phillips I, Casewell M, Cox T, de Groot B, Friis C, Jones R, Nightingale C, Preston R, Waddell J published in J. Antimicrob. Chemother. 2004; 54 (1): 276-278

Development of a standardized susceptibility test for Campylobacter with quality control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem. by McDermott P, Bodeis S, Aarestrup F, Brown S, Traczewski M, Fedorka-Cray P, Wallace M, Critchley I, Thornsberry C, Graff S, Flamm R, Beyer J, Shortridge D, Piddock L, Ricci V, Johnson M, Jones R, Reller B, Mirrett S, Aldrobi J, Rennie R, Brosnikoff C published in Microbial. Drug Resist. 2004; 10 (2): 124-131

In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. by Fritsche TR, Kirby JT and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 49 (3): 201-209

Determination of epidemic clonality among multi-drug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003). by Jones RN, Deshpande L, Fritsche TR, Sader HS published in Diagn. Microbiol. Infect. Dis. 2004; 49 (3): 211-216

Quality control guidelines for BAL9141 (RO 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used. by Anderegg TR, Jones RN and Sader HS published in J. Clin. Microbiol. 2004; 42 (7): 3356-3358

Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: Results from five years of the SENTRY Antimicrobial Surveillance Program. by Castanheira M, Gales AC, Mendes RE, Jones RN and Sader HS published in Clin. Microbiol. Infect. 2004; 10 (7): 645-651

Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002). by Jones RN, Sader HS and Fristche TR published in Diagn. Microbiol. Infect. Dis. 2004; 49 (2):147-149

Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY Program, 1999 to 2001. by Christiansen KJ, Bell JM, Turnidge JD, Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (6): 2049-2055

Emergence of the extended-spectrum beta-lactamase GES-1 in a Pseudomonas aeruginosa strain from Brazil: Report from the SENTRY Antimicrobial Surveillance Program. by Castanheira M, Mendes RE, Walsh TR, Gales AC and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (6): 2344-2345

Antibiotic use in animals. by Phillips I, Casewell M, Cox T, DeGroot B, Friis C, Jones RN, Nightingale C, Preston R, Waddell J published in J. Antimicrob. Chemother. 2004; 53 (5): 885

Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. by Ambrose PG, Anon JB, Owen JS, Van Wart S, McPhee ME, Bhavnani SM, Piedmonte M and Jones RN published in Clin. Infect. Dis. 2004; 38 (11): 1513-1520

Antimicrobial spectrum and activity of NVP PDF-713, A novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates. by Jones RN, Fritsche TR and Sader HS published in Diagn. Microbiol Infect. Dis. 2004; 49 (1): 63-65

Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. by Jones RN, Moet GJ, Sader HS and Fritsche TR published in J. Antimicrob. Chemother. 2004; 53 (5): 804-807

Daptomycin activity and spectrum: A worldwide sample of 6,737 clinical Gram-positive organisms. by Streit JM, Jones RN, Sader HS published in J. Antimicrob. Chemother. 2004; 53 (4): 669-674

Letters to the editor: First isolation of bla_VIM-2 in Latin America: Report from the SENTRY Antimicrobial Surveillance Program. by Mendes RE, Castanheira M, Garcia P, Guzman M, Toleman MA, Walsh TR and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (4): 1433-1434

A pragmatic approach to identify extended-spectrum beta-lactamse-producing Klebsiella pneumoniae in Taiwan: in vitro activity of newer and established antimicrobial agents. by Yu, W-L, Chuang, Y-C, Jones, RN published in Diagn. Microbiol. Infect. Dis. 2004; 48 (4): 277-282

Pseudomonas aeruginosa strains harbouring an unusual bla_VIM-4 gene cassette isolated from hospitalized children in Poland (1998-2001). by Patzer J, Toleman MA, Deshpande LM, Kaminska W, Dzierzanowska D, Bennett PM, Jones RN and Walsh TR published in J. Antimicrob. Chemother. 2004; 53 (3): 451-456

Quality control guidelines for MIC susceptibility testing of omiganan pentahydrochloride (MBI226), a novel antimicrobial peptide. by Anderegg T.R., Fritsche TR and Jones RN published in J. Clin. Microbiol. 2004; 42 (3): 1386-1387

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. by Streit JM, Fritsche TR, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 48 (2): 137-143

In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. by Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 48 (2): 101-105

Antibiotic resistance in hospitalized patients: MYSTIC Program (1999-2002). by Rhomberg PR, Fritsche TR, Sader HS, Jones RN published in Antibiot. Clin. 2003; 7 (Suppl 2): 2-7

Comparisons of the in vitro susceptibility testing results for garenoxacin using six different national methods: Report from the Garenoxacin International Bridging Study. by Jones RN, Gordon KA, Biedenbach DJ published in J. Antimicrob. Chemother. 2004; 53 (2): 258-265

Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). by Mutnick AH, Rhomberg PR, Sader HS, Jones RN published in J. Antimicrob. Chemother. 2004; 53 (2): 290-296

Disk diffusion quality control guidelines for NVP PDF-713: A novel peptide deformylase inhibitor. by Anderegg TR, Jones RN, The Quality Control Working Group published in Diagn. Microbiol. Infect. Dis. 2004; 48 (1): 55-57

Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. by Jones RN, Streit JM and Fritsche TR published in Int. J. Antimicrob. Agents. 2004; 23 (2): 197-199

Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of the 2001 data from 15 United States Medical Centres. by Rhomberg PR, Jones RN, Sader HS and MYSTIC Programme Study Group published in Int. J. Antimicrob. Agents 2004; 23 (1): 52-59

Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone. by Anderegg TR and Jones RN published in Int. J. Antimicrob. Agents 2004; 23 (1): 6-10

Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp.: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001). by Kirby JT, Sader HS, Walsh TR and Jones RN published in J. Clin. Microbiol. 2004; 42 (1): 445-448

Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data. by Phillips I, Casewell M, Cox T, De Groot B, Friis C, Jones RN, Nightingale C, Preston R, Waddell J published in J. Antimicrob. Chemother. 2004; 53 (1): 28-52

Emergence of two Klebsiella pneumoniae isolates harboring plasmid-mediated CTX-M-15 beta-lactamase in Taiwan. by Yu W-L, Wu L-T, Pfaller MA, Winokur PL and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (1): 362-363

bla_VIM-7, an evolutionary distinct metallo-beta-lactamsae gene in a Pseudomonas aeruginosa isolate from the United States. by Toleman MA, Rolston K, Jones RN and Walsh TR published in Antimicrob. Agents Chemother. 2004; 48 (1): 329-332

Are Enterococcus faecalis strains with vat(E) in poultry a reservoir for human streptogramin resistance? vat(E) occurrence in human enterococcal bloodstream infections in North America (SENTRY Antimicrobial Surveillance Program, 2002). by Jones RN, Deshpande LM published in Antimicrob. Agents Chemother. 2004; 48 (1): 360-361

In vitro activities of the novel cephalosporin LB11058 against multidrug-resistant staphylococci and streptococci. by Sader HS, Johnson DM and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (1): 53-62